OncoMatch/Clinical Trials/NCT04087421
Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome
Is NCT04087421 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Qufora Irrisedo Cone System and Glycerol "OBA" for low anterior resection syndrome.
Treatment: Qufora Irrisedo Cone System · Glycerol "OBA" — The study is a multicentre randomized controlled trial with the objective to compare the effect of transanal irrigation with glycerol suppositories in patients suffering from major Low Anterior Resection Syndrome (LARS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Prior therapy
Must have received: surgical resection — low anterior resection for rectal cancer
Patients electively treated for rectal cancer with a low anterior resection.
Must have received: treatment for LARS — PCT (presumably pelvic floor/physical therapy or similar) for at least 4 weeks
Unsuccessful PCT after at least 4 weeks of treatment for LARS
Cannot have received: transanal irrigation
Former use of TAI
Cannot have received: systematic use of rectal emptying aids
Prior systematic use of rectal emptying aids
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify